Federal Register / Vol. 78, No. 106 / Monday, June 3, 2013 / Notices 33097 

Ron A. Otten, 

Director, Office of Scientific Integrity, Office 

of the Associate Director for Science, Office 

of the Director, Centers for Disease Control 

and Prevention. 

[FR Doc. 2013–12978 Filed 5–31–13; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[CDC–2013–0007; NIOSH–233] 

NIOSH List of Antineoplastic and Other 

Hazardous Drugs in Healthcare 

Settings 2014: Proposed Additions and 

Deletions to the NIOSH Hazardous 

Drug List 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of Draft Document 

Available for Public Comment. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) 

announces the availability of the 

following draft document for public 

comment entitled ‘‘NIOSH List of 

Antineoplastic and Other Hazardous 

Drugs in Healthcare Settings 2014: 

Proposed Additions and Deletions to the 

NIOSH Hazardous Drug List.’’ The 

document and instructions for 

submitting comments can be found at 

http://www.regulations.gov. 

This guidance document does not 

have the force and effect of law. 

Public Comment Period: Comments 

must be received by August 2, 2013. 

ADDRESSES: You may submit comments, 

identified by CDC–2013–0007 and 

Docket Number NIOSH–233, by either 

of the two following methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: NIOSH Docket Office, Robert 

A. Taft Laboratories, MS–C34, 4676 

Columbia Parkway, Cincinnati, Ohio 

45226. 

Instructions: All information received 

in response to this notice must include 

the agency name and the docket number 

(CDC–2003–0007; NIOSH–233). All 

relevant comments received will be 

posted without change to http:// 

www.regulations.gov, including any 

personal information provided. All 

electronic comments should be 

formatted as Microsoft Word. Please 

make reference to CDC–2013–0007 and 

Docket Number NIOSH–233. 

SUPPLEMENTARY INFORMATION: 

Background: The NIOSH Alert: 

Preventing Occupational Exposures to 

Antineoplastic and Other Hazardous 

Drugs in Health Care Settings was 

published in September 2004 (http:// 

www.cdc.gov/niosh/docs/2004-165/). 

This Alert contained Appendix A which 

was a list of drugs that were deemed to 

be hazardous and may require special 

handling. This list of hazardous drugs 

was updated in 2010 and 2012 and 

covered all new approved drugs and 

drugs with new warning up to 

December 2009. (http://www.cdc.gov/ 

niosh/docs/2010-167/; http:// 

www.cdc.gov/niosh/docs/2012-150/). 

Between January 2010 and December 

2011, 48 new drugs received FDA 

approval and 276 drugs received special 

warnings (usually black box warnings) 

based on reported adverse effects in 

patients. From this list of 324 drugs, 42 

drugs were identified by NIOSH as 

candidate hazardous drugs. Four of 

these drugs had safe handling 

recommendations from the 

manufacturer and NIOSH is following 

the recommendations of the 

manufacturers. Therefore, these four 

drugs will be listed as hazardous 

without requiring further review. A 

panel consisting of peer reviewers and 

stakeholders was asked to review and 

comment on the remaining 38 

potentially hazardous drugs. In 

addition, the panel members were asked 

to comment on the addition of one drug 

requested by several stakeholders and 

the removal of one drug from the 2012 

Hazardous Drug List. Reviewers were 

not asked to provide a consensus 

opinion and NIOSH made the final 

determination regarding additions and 

deletions to the 2014 hazardous drug 

list. 

NIOSH reviewed the 

recommendations of the peer reviewers 

and stakeholders and determined that 

24 drugs in addition to the 4 drugs with 

manufacturer’s warnings, were 

determined to have one or more 

characteristics of a hazardous drug and 

this list of 28 drugs is being published 

for comment in CDC–2013–0007 and 

NIOSH Docket Number 233. In addition, 

1 drug from the 2012 Hazardous Drug 

List is being considered for removal. 

The complete list of these drugs can be 

found at: http://www.regulations.gov as 

a supporting document. 

FOR FURTHER INFORMATION CONTACT: 

Barbara MacKenzie, NIOSH, Robert A. 

Taft Laboratories, 4676 Columbia 

Parkway, MS–C26, Cincinnati, Ohio 

45226, telephone (513) 533–8132, Email 

hazardousdrugs@cdc.gov. 

Dated: May 24, 2013. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2013–13043 Filed 5–31–13; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request: Generic Clearance 

for the Collection of Qualitative 

Feedback on Agency Service Delivery, 

National Institute of Neurological 

Disorders and Stroke (NINDS) 

SUMMARY: As part of a Federal 

Government-wide effort to streamline 

the process to seek feedback from the 

public on service delivery, the National 

Institute of Neurological Disorders 

(NINDS) has submitted a Generic 

Information Collection Request (Generic 

ICR): ‘‘Generic Clearance for the 

Collection of Qualitative Feedback on 

Agency Service Delivery’’ to OMB for 

approval under the Paperwork 

Reduction Act (PRA) (44 U.S.C. 3501 et. 

seq.). 

DATES: Comments must be submitted 

within 30 days after publication in the 

Federal Register. 

ADDRESSES: Written comments may be 

submitted to the Office of Management 

and Budget, Office of Information and 

Regulatory Affairs, Attn: NIH Desk 

Officer, by Email to 

OIRA_submission@omb.eop.gov, or by 

fax to 202–395–6974. 

FOR FURTHER INFORMATION CONTACT: To 

request additional information, please 

contact: Paul Scott, Ph.D., Director, 

Office of Science Policy and Planning, 

NINDS, 31/8A03 Center Drive, 

Bethesda, MD 20892–2178, or Email 

your request, including your address to 

scottp@ninds.nih.gov. 

SUPPLEMENTARY INFORMATION: 

Title: Generic Clearance for the 

Collection of Qualitative Feedback on 

Agency Service Delivery. 

Abstract: The information collection 

activity will garner qualitative customer 

and stakeholder feedback in an efficient, 

timely manner, in accordance with the 

Administration’s commitment to 

improving service delivery. By 

qualitative feedback we mean 

information that provides useful 

insights on perceptions and opinions, 


sroberts on DSK5SPTVN1PROD with NOTICES